Lucid Diagnostics Earnings beat, Revenue misses In Q3

  • Investing.com
Lucid Diagnostics Earnings beat, Revenue misses In Q3
Credit: © Reuters.

Investing.com - Lucid Diagnostics reported on Monday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.

Lucid Diagnostics announced earnings per share of $-0.28 on revenue of $76K. Analysts polled by Investing.com anticipated EPS of $-0.35 on revenue of $431.38K.

Lucid Diagnostics shares are down 30% from the beginning of the year and are trading at $2.27 , down-from-52-week-high.

Lucid Diagnostics follows other major Healthcare sector earnings this month

Lucid Diagnostics's report follows an earnings beat by J&J on Tuesday, October 18, 2022, who reported EPS of $2.55 on revenue of $23.79B, compared to forecasts EPS of $2.48 on revenue of $23.36B.

Eli Lilly had beat expectations on Tuesday, November 1, 2022 with third quarter EPS of $1.98 on revenue of $6.94B, compared to forecast for EPS of $1.91 on revenue of $6.91B.

Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or

100